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Abstract
To estimate the frequency, molecular epidemiological and clinical associations of infection with the newly described species
C variants of human rhinoviruses (HRV), 3243 diagnostic respiratory samples referred for diagnostic testing in Edinburgh
were screened using a VP4-encoding region-based selective polymerase chain reaction (PCR) for HRV-C along with parallel
PCR testing for 13 other respiratory viruses. HRV-C was the third most frequently detected behind respiratory syncytial virus
(RSV) and adenovirus, with 141 infection episodes detected among 1885 subjects over 13 months (7.5%). Infections
predominantly targeted the very young (median age 6–12 months; 80% of infections in those ,2 years), occurred
throughout the year but with peak incidence in early winter months. HRV-C was detected significantly more frequently
among subjects with lower (LRT) and upper respiratory tract (URT) disease than controls without respiratory symptoms;
HRV-C mono-infections were the second most frequently detected virus (behind RSV) in both disease presentations (6.9%
and 7.8% of all cases respectively). HRV variants were classified by VP4/VP2 sequencing into 39 genotypically defined types,
increasing the current total worldwide to 60. Through sequence comparisons of the 59untranslated region (59UTR), the
majority grouped with species A (n=96; 68%, described as HRV-Ca), the remainder forming a phylogenetically distinct
59UTR group (HRV-Cc). Multiple and bidirectional recombination events between HRV-Ca and HRV-Cc variants and with HRV
species A represents the most parsimonious explanation for their interspersed phylogeny relationships in the VP4/VP2-
encoding region. No difference in age distribution, seasonality or disease associations was identified between HRV-Ca and
HRV-Cc variants. HRV-C-infected subjects showed markedly reduced detection frequencies of RSV and other respiratory
viruses, providing evidence for a major interfering effect of HRV-C on susceptibility to other respiratory virus infections. HRV-
C’s disease associations, its prevalence and evidence for interfering effects on other respiratory viruses mandates
incorporation of rhinoviruses into future diagnostic virology screening.
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Introduction
Human rhinoviruses (HRVs) are members of the recently
expanded Enterovirus genus within the family Picornaviridae [1].
Their genome organisation and structure are typical for
picornaviruses, possessing a 7200 base single stranded RNA
genome and a non-enveloped virion of approximately 30 nm in
diameter. Human rhinoviruses were originally classifiable into two
species, A and B with likely distinct evolutionary separate origins
within the Enterovirus genus. However, they both share a primary
tropism for the respiratory tract and species B and most species A
variants use the intracellular adhesion molecule-1 receptor for
entry [2]. Being acid-labile, HRVs do not colonise the gut, and are
most commonly transmitted by the respiratory-salivary route, both
by person-to-person contact and airborne transmission. In
temperate countries, infections occur primarily in two peaks, the
first between April and May and the second between September
and October [3,4].
Recent wider use of molecular detection methods in viral
diagnostic screening has revealed the quite unexpected existence of
a further species of human rhinoviruses [5–11]. These species C
rhinoviruses (HRV-Cs) have been shown to be highly prevalent,
with initial studies demonstrating frequent detection of this species
in association with bronchiolitis and other lower respiratory tract
disease [9,12–14], in asthma exacerbations [9,14–16] and otitis
media [17].
HRVs show remarkable genetic and antigenic heterogeneity,
with 74 and 25 serotypes being classified by cross-neutralisation
assays in species A and B viruses respectively. Although species C
variants have not yet been isolated or cultured in vitro and therefore
cannot be formally assigned into separate serotypes, existing
sequence data reveals perhaps even greater genetic heterogeneity
than found within HRV-A and HRV-B. The large number of
distinct genetic lineages identifiable by sequence comparisons in the
VP4/VP2 gene regionmaythus correspond to different serotypes of
HRV-C [13,18,19]. Furthermore, sequence divergence in VP1 and
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different HRV-A or –B serotypes, implying the existence of major
antigenic differences that influence immunological cross-protection
in this newly discovered species. An additional aspect of HRV-C
genetic diversity that has caused confusion in previous attempts at
HRV species identification and typing is the occurrence of
recombination between HRV-A and HRV-A in the 59 untranslated
region (59UTR). While species A and B rhinoviruses have
phylogenetically distinct sequences in this region, those from the
majority of HRV-C variants resemble those of species A [19–21],
while the remainder form a phylogenetically separate group distinct
from HRV-A and HRV-B and other enterovirus species. Initial
data however shows no differences in clinical presentations between
HRV-C variants with A and C 59UTR-like sequences (described as
HRV-Ca and HRV-Cc respectively [19]; this nomenclature will be
followed in the current study).
In the current study we have developed a selective VP4 gene
PCR-based amplification method for specific detection of HRV-C
in respiratory specimens. This has enabled us to screen and
clinically characterise infections occurring over a whole calendar
year (13 months) in a study group of more than 1800 subjects.
Parallel screening for other human respiratory viruses over the
same period allowed us to directly compare their epidemiologies
and association with specific disease presentations.
Results
Development of a Method for Selective Screening of
HRV-C
The intention of the study was the investigation of the incidence,
genetic variability and clinical presentation of HRV-C collected
over a whole calendar year. Non-selective amplification of all
HRV (and HEV) species using previously developed 59UTR-
based PCR methods would have identified an extremely large
number of non-HRV-C positive samples that would preclude
effective screening using pools. To overcome this, we modified the
VP4/VP2-encoding region PCR previously used for genetic
characterisation and (sero)type identification of HRV to enable
selective amplification of HRV-C. The inner antisense primer was
repositioned to a more variable position in the VP4 gene between
species A, B and C sequences to enable selective hybridisation and
strand extension of HRV-C sequences. The sensitivity and
specificity of the selective PCR was evaluated using samples
previously identified as HRV-A, -B and –C variants in a previous
study [18]. All 26 species C samples were positive, along with 1
from 63 species A and 1 from 8 species B samples in the assay
(sensitivity 100%; 98% specificity). Since all positive samples were
to be sequenced in the more variable VP4/VP2-encoding region,
this minor degree of non-specificity would not influence our
identification of HRV-C positive samples for the study.
Detection of HRV-C in Respiratory Samples
Excluding those samples from September 2006 and February
2007 already tested as controls for assay validation, the assay was
used for screening the remaining samples between September
2006 and September 2007. These comprised a total of 2787
samples collected from 1540 study subjects initially combined into
pools of 10 and with positive pools split and re-tested as previously
described [22].
A total of 162 samples were positive on initial screening. On
nucleotide sequencing of the amplified VP4/VP2 gene region, 144
samples were identified as belonging to species C, the remainder
comprising HRV-A (n=15), HRV-B (n=2) and human entero-
virus species B (n=1). The selective primers were therefore
moderately effective at selective amplification of species C variants
with an overall specificity of 89% in a screened population (where
HRV species A predominates; [18]). Screening data from the
selective primers was combined with results from our previous
screening of 456 samples collected in September, 2006 and
February, 2007 [18] to yield a combined sample and study group
of 175 HRV-C positive samples originating from 130 different
individuals, to which further results will refer.
Sequences amplified and sequenced in the VP4/VP2-encoding
region were compared with those obtained in previous studies
(sequence download from GenBank in August, 2009). Amongst the
latter previously deposited sequences, a total of 54 putative HRV-
C (geno)types could be assigned using previously described criteria
(VP4/VP2 gene phylogeny and a pairwise distance threshold of
0.1; [18]). Through the same comparative method, study samples
comprised 39 types (Fig. 1), of which 6 were distinct from
previously deposited HRV-C sequences, producing a combined
total of 60.
Frequencies of re-infection and persistence of HRV-C among
subjects who contributed more than one positive sample over the
study period were estimated by sequence comparisons in the VP4/
VP2-encoding region. For the 13 subjects who were repeatedly
positive for HRV-C in the same calendar month, VP4/VP2 gene
sequences were similar or identical, while those with positive
samples separated by one month or longer were invariably infected
with different HRV-C types. The close concordance between
sample timing and evidence for re-infection allowed us to identify
separate infection episodes in 11 of the subjects. The only exception
to this correlation was a long-term hospitalised patient with acute
myeloid leukaemia, who was regularly screened through the 13
month study period and from whom a total of 12 positive samples
(from 19 collected) were obtained. The close sequence similarity of
HRV-C variants over this period (marked in Fig. 1, subject ID
4235677556)indicatedlong-termpersistentHRV-C infectioninthe
context of likely severe immunosuppression.
HRV-C Recombination
The 59UTR group of each of the HRV-C positive samples in
the study was determined by amplification and sequencing of a
region between 280–370 in the 59UTR. This analysis was assisted
by inclusion of those published HRV-C for which VP4/VP2 gene
sequences and 59UTR groups had been determined (including the
9 available complete genome sequences of HRV-C; data not
shown). The majority of HRV-C variants characterised in the
current study from separate infection episodes (96 from 141; 68%)
contained species A-like 59UTR sequences, termed HRV-Ca [19].
Clades and HRV-C types with different 59UTR groups (HRV-Ca
and HRV-Cc) were interspersed within the VP4/VP2 gene tree
(Fig. 1), implying the existence of multiple recombination events in
the past diversification of HRV-C. In general, all variants of the
same (geno)type assigned in the VP4/VP2-encoding region
contained the same 59UTR group. There were however, two
exceptions, the HRV-Ca samples R3856/07 clustered closely with
HRV-Cc variants (Fig. 1) and there was a split of one of the
genotypes into HRV-Ca (published sequences from China) HRV-
Cc (7 samples amplified from 5 different study subject from
Edinburgh). These observations imply ongoing, bi-directional and
frequently recent recombination events between rhinoviruses with
different 59UTR groups.
Epidemiological and Clinical Associations of HRV-C
Epidemiological and clinical information on the study samples
and subjects retained through the anonymisation process was used
to compare seasonal and age distribution of HRV-C infections
HRV-C Diversity, Interactions
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In contrast to RSV and influenza A virus which showed
pronounced increases in incidence in winter months, HRV-C
infections occurred year round with similar incidence in each
calendar month investigated in the current study (Fig. 2A), more
comparable to adenovirus. In contrast, HRV-C resembled RSV
closely in targeting young children and infants, with peak
incidence of both viruses occurring in the 4–6 month age range,
with a younger age distribution than adenovirus infections and
distinct from the wide age range of influenza A virus (Fig. 3). 85%
of HRV-C infections were observed in children younger than 2
years of age. No systematic difference was evident between HRV-
Ca and HRV-Cc in their seasonal distribution or age range of
infection.
Detection frequencies of HRV-C and other respiratory viruses
among subjects presenting with LRTIs, URTIs and those without
respiratory symptoms were compared (Fig. 4). Subjects compared
were those presenting acutely and excluded those with underlying
immunosuppression or severe underlying disease (see Methods for
criteria to assign disease categories). One or more respiratory virus
was detected in 55% of subjects with LRTIs, 65% in URTIs and
22% in those with no relevant respiratory or other symptoms/
diagnoses. Dividing these groups, HRV-C was the only virus
detected in 6.9% of LRTI cases and in 7.8% in URTIs, higher
than in the non-respiratory disease controls (3.7%) and second
only to RSV in detection frequency (15.7% and 10.0%
respectively). HRV-C was twice as frequently detected in subjects
with respiratory disease than in those without relevant symptoms
(p=0.009 by Chi-squared test). HRV-C was detected in children
in paediatric intensive care units (12%, 14 patients), mostly with
pneumonia and without any other cause identified, in neonatal
intensive care (11%, 4 patients). There was no significant
difference between disease categories in the proportion of HRV-
Ca and HRV-Cc variants.
Virus Interference
Evidence for significant interactions between respiratory viruses
was obtained through comparisons of detection frequencies in
mono- and doubly-infected individuals (Fig. 5). HRV-C was nearly
three times more commonly detected in those co-infected with
adenovirus (16.0%) than in mono-infected subjects (5.8%;
p,0.001). Examples of negative interactions were additionally
observed. Most strikingly, HRV-C had a highly significant effect
on detection frequencies of RSV and other respiratory viruses.
RSV mono-infection was found in 10.7% samples but virtually
absent among HRV-C infected subjects (2.4%, p,0.001). For
other respiratory viruses (excluding AdV), a 3.5-fold reduction in
their infection frequency was observed in HRV-C co-infected
subjects (12.9% to 3.7%; p,0.001). This reduction was greater
than the effect of RSV co-infection on their detection frequency
(,2-fold). In contrast, RSV and the group of other respiratory
viruses did not significantly influence the likelihood of HRV-C
detection; study subjects showed a 5.8% HRV-C mono-infection
frequency compared to 4.6% and 8.6% in those co-infected with
RSV and other respiratory viruses respectively (p.0.05). Together
these observations indicate that it is HRV-C that is inhibiting RSV
and other respiratory infections rather than the converse.
Discussion
Detection Frequency and Type Identification of HRV-C
This study represents one of the first large scale investigations of
the epidemiology and clinical impact focussed on the newly
discovered species C rhinoviruses, and provides evidence for its
Figure 1. Phylogeny of VP4/2 gene sequences amplified from
study subjects and comparison with corresponding full length
sequences ofHRV-C and other samples where 59UTR groups had
been previously assigned [19]. Symbols identify HRV-Cc (ie. with
species C-like 59UTR sequences) or HRV-Ca (species A-like) as described in
the key. The neighbour-joining tree was constructed using maximum
composite likelihood distances estimated between sequences in the
amplified region (positions 629–1063 numbered according to the HRV-
B14 reference sequence(NC_001490).Datawasbootstrap re-sampled100
times to assess robustness of branches; values of 70% or greater shown.
Sequences showing incompatibilities between 59UTR and phylogenetic
grouping in VP4/VP2 suggestive of recombination are arrowed.
doi:10.1371/journal.pone.0008518.g001
HRV-C Diversity, Interactions
PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8518Figure 2. Seasonal distribution of (A) HRV-C positive samples and (B) those positive for other common respiratory viruses. The y-axis
depicts the proportion of samples positive from the total in each category (shown above each bar in part A). Frequencies of HRV-C detection have
been subdivided into HRV-Ca and HRV-Cc subgroups.
doi:10.1371/journal.pone.0008518.g002
Figure 3. Age distribution of (A) HRV-C infected subjects and (B) those infected with other common respiratory viruses. The y-axis
depicts the proportion of subjects positive from the total in each category. Frequencies of HRV-C detection have been subdivided into HRV-Ca and
HRV-Cc subgroups.
doi:10.1371/journal.pone.0008518.g003
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third most prevalent virus in the study population with 141
infection episodes detected among 1885 subjects over a 13 month
period (7.5%), with only RSV (14.2%) and adenovirus (11.5%)
being detected more frequently. Through genetic comparisons of
the VP4/VP2-encoding region, HRV-C infections were found to
be almost invariably acute/resolving with no evidence for
persistence among multiply sampled individuals with the single
exception of an immunocompromised child with AML. Where
re-infection did occur, it was invariably by another HRV-C type,
consistent with the hypothesis that species C types that have been
assigned on the basis of VP4/VP2 gene sequence divergence,
might nevertheless be antigenically distinct and capable of
infection in those exposed previously to heterologous types. These
findings are consistent with previous observations for a 10–21 day
period of virus shedding of HRV in immunocompetent individuals
[23–26]. Given the high incidence of HRV infections and ongoing
exposure to other circulating (sero)types, molecular characterisa-
tion is required to clearly document HRV persistence [27].
Contributing to the high incidence of HRV-C is its genetic (and
likely antigenic) diversity, evident among the variants detected in
the current study and through analysis of published sequences in
the VP4/VP2-encoding region where a total of 60 types could be
provisionally assigned. Although nucleotide sequence divergence
in this region can only be used indirectly to infer antigenic
variability in other parts of the genome, the 10% pairwise distance
threshold in VP4/VP2-encoding region matched the divergence
that effectively categorises HRV species A and B into their 74 and
25 constituent serotypes [18]. Sequence comparisons in the VP4/
VP2-encoding region thus remain a useful provisional assignment
tool until sequences from the whole capsid-encoding region
become available.
HRV-C Recombination
Through sequence comparisons in the 59UTR of the samples
identified as positive on VP4 gene screening, it was possible to
classify the 175 positive samples into two groups, those with a
59UTR sequence similar to species A rhinoviruses described as
HRV-Ca [19] and those clustering separately from species A and
B (and from human enteroviruses) described as HRV-Cc. The
complete genome sequence N10 [19] falls into the HRV-Cc group
while the eight others available, including the species C prototype
strain QPM possess 59UTR sequences groups within HRV species
A sequences (HRV-Ca). Apart from the complete genome
sequences, published sequence data from both the 59UTR and
VP4/VP2 gene regions is only available from 34 Chinese species
C strains [19]. These were classified into 20 HRV-Ca and 14
HRV-Cc variants. Other studies from South Korea [21] and Italy
[26] separated species C variants into HRV-Ca and HRV-Cc
groups, although VP4/VP2 gene sequences were not deposited
onto GenBank/EMBL and could not be included in the analysis in
Fig. 1.
The multiple interspersed phylogenetic positions of VP4/VP2-
encoding sequences from HRV-Ca and HRV-Cc variants is
consistent with multiple inter-species recombination events in the
evolutionary history of human rhinoviruses. We do not know and
likely cannot reconstruct the actual evolutionary steps that created
the complex phylogeny relationships in this genomic region, or the
nature of the ancestors of currently circulating species A and C
Figure 4. Detection frequency of HRV-C and other respiratory
viruses among subjects presenting with symptoms or diagno-
ses of LRTIs, URTIs and those with no relevant (NR) respiratory
symptoms. For the purposes of this analysis, cough was considered a
symptom of URTI.
doi:10.1371/journal.pone.0008518.g004
Figure 5. Analysis of potential virus interference through
comparison of mono- and co-infection frequencies. Each of the
three most frequently detected respiratory viruses (HRV-C, RSV and
AdV) and a combined group of all others (influenza A and B, PIV1-3,
hMPV, coronaviruses, HBoV, HPeV) were separately analysed (x-axis,
top). For each, mono-infection frequencies (unfilled bars) were
compared with those where HRV-C, RSV, AdV and other respiratory
viruses were co-detected (indicated on bottom x-axis, grey filled boxes).
The existence of statistically significant differences in frequencies was
determined by chi-squared test; NS: not significant.
doi:10.1371/journal.pone.0008518.g005
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the scattering of HRV-Cc and HRV-Ca variants in the VP4/VP2
tree is a series of recombination events early in the diversification
of the ancestor of HRV-C into the current large number of types
that now exist. Had there been only one recombination event
between species A and C, the descendants of the original
recombinant (with its more recent evolutionary origin relative to
rhinoviruses circulating at that time) would be expected to have
remained more closely related to each other (monophyletic) in
both 59UTR and VP4/VP2 gene regions (and elsewhere in the
genome). This is clearly not the case in the VP4/VP2 gene region
(Fig. 1) or in the 59UTR; published HRV-Ca variants (those of
complete genome sequences and from China) fall into at least two
separate groups in the latter region [19]. The occurrence of
multiple recombination events is consistent with recent observa-
tions for differences in the recombination breakpoints between
different HRV-Ca and HRV-Cc variants [19].
The observation that variants within a species C type usually
had the same 59UTR group (Fig. 1) suggests that most
recombination occurred early in the diversification of HRV-C.
However, a variant in the current study differed in 59UTR group
from other members of the same type (the HRV-Ca strain R3856/
07 clustered with HRV-Cc variants). Although these anomalous
results have been verified by independent re-extraction and re-
amplification of the sample and other members of the clades into
which it grouped, it remains formally possible that the study
subject was co-infected with two different rhinovirus variants. PCR
assays using 59UTR and VP4/VP2 gene primers may have
amplified a different (species A-like) 59UTR sequence from that
possessed by the species C virus sequenced in the VP4 gene.
Notwithstanding this, another recent (intra-typic) recombination
event could be inferred between a cluster of closely related HRV-
Cc variants from the current study and several published HRV-Ca
sequences from China that are of the same species C type (Fig. 1).
Given this evidence for frequent and likely ongoing recombina-
tion, it remains difficult to explain why there are no known species
A rhinovirus recombinants with species C 59UTR sequences;
perhaps ongoing recombination events are restricted to those
between HRV-Ca and HRV-Cc.
In many respects, the phylogeny relationships observed in
rhinoviruses in 59UTR and coding regions resemble those of
human enteroviruses. Santti et al. [28] showed that 59UTR
sequences from HEV-A and -B were similarly interspersed in this
region, as were sequences from species C and D, implying a
similar process of frequent interspecies recombination. Whether
inter-species recombination in rhinovirus species C (or indeed
among enteroviruses) confers an evolutionary advantage remains
unclear. Observations for its (likely) multiple occurrence in species
C and the absence of species A rhinoviruses with group C 59UTR
sequences suggests that possession of group A 59UTR may be
advantageous. However, no evidence was gained in this study for
any distinct epidemiological features or in their clinical presenta-
tions that might originate from hypothesised fitness differences
between HRV-Ca and HRV-Cc groups.
Clinical Presentations of HRV-C
Comprehensive screening for HRV-C over a whole calendar
year enabled seasonality of infections, target groups and clinical
associations of HRV-C infections to be compared with those of
other respiratory viruses. The large number of HRV-C infection
episodes detected over this period allowed a number of relatively
robust conclusions to be drawn. Firstly, the study identifies young
children and infants as the main target group for HRV-C infection
among predominantly hospitalised individuals, with an age profile
comparable to that of RSV. For both viruses, over 80% of
infections were observed in those less than 2 years of age (Fig. 3),
higher than in AdV (77%), influenza A virus (44%) and other
respiratory viruses (63%). The targeting of very young children
was comparable to that observed for HRV species A (80%; [18])
and in previous investigations of all three HRV species
[13,14,29,30]. HRV-C similarly resembled other rhinovirus
species in its seasonal distribution (Fig. 2), circulating throughout
the year as reported for other rhinoviruses [3,13,25,29,31]. It did
not however show the typically higher incidence in autumn found
in other rhinoviruses (and human enteroviruses), and actually
showed higher infection frequencies in winter months. However, a
longer study period would be required to discount the effect of
year-on-year fluctuations in the incidence of species C.
It is increasingly recognised that HRVs are collectively
underestimated as a cause of significant respiratory illness
[27,32]. The frequent detection of HRV-C mono-infection in a
substantial proportion of subjects presenting with LRTIs and
URTIs (Fig. 4) is concordant with recent PCR-based studies
[13–17,29,33,34] that demonstrate a numerically significant role
for HRV-C and other rhinovirus species in severe respiratory
disease requiring hospitalisation in children and exacerbation of
asthma. Detection frequencies of 7–8% for HRV-C in subjects
with URTIs or LRTIs was significantly higher than in those
presenting without respiratory disease in the current study (3.7%),
although this approximate two-fold difference in frequency was
less than observed between these categories for RSV and hMPV
(4- and 6.5-fold), parainfluenza viruses (5-fold), but greater than for
adenoviruses and coronaviruses (1.5- and 1.8-fold) and other
viruses (HBoV/HPeV; equal frequencies). To our knowledge,
there is no published information on the rate of asymptomatic
infections with species C rhinoviruses in hospitalised patients or in
the general community. However, total HRV detection frequen-
cies determined by PCR have produced highly variable results
(2–61%; reviewed in [27]), although averaging to 15% [35].
Taking this latter average estimate, and assuming that species C
variants constitute a quarter or a third of all HRV detections (as
previously found in a subset of the current study population; [18]),
then the 4%–5% predicted prevalence matches closely to that of
the control group in the current study. The increased frequency in
the LRTI and URTI groups is therefore consistent with its
proposed aetiological role in respiratory disease among the
predominantly hospitalised study subjects in the current study.
Further prospectively collected information on disease severity and
symptoms, along with viral load information on study subjects and
controls are, however, required to further substantiate the findings
reported here.
HRV and Co-Infection Frequency
In the current study, all samples were screened for an extended
range of human respiratory viruses (influenza A and B viruses,
RSV, AdV and PIV1-3, hMPV, HBoV, HPeV and coronavirus-
es). This allowed a detailed investigation of frequencies of virus
co-infections among subjects presenting with respiratory illnesses
and potential interactions (positive and negative) between them.
The most striking observation was the evidence for interference of
RSV and other respiratory viruses (except adenovirus) by HRV-C.
For example, the 10.7% detection frequency of RSV among
single-infected individuals was markedly reduced among those
co-infected with HRV-C (2.4%). A comparable reduction was
observed in the ‘‘other virus’’ category (predominantly parainflu-
enza and coronaviruses with a 3.5-fold difference). RSV showed a
more modest effect on detection frequencies in this latter category
(less than two-fold reduction). The further observation that the
HRV-C Diversity, Interactions
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HRV-C detection frequencies is consistent with HRV-C interfer-
ing with susceptibility to infection with other RNA viruses rather
than the opposite. Negative interactions in detection frequency
and viral loads comparable to those observed between these RNA
virus groups have been previously described between different
pairs of respiratory viruses, and report significant interfering effects
of HRV (all species) on RSV and a range of other RNA viruses
[36,37]. In contrast to the latter study, we additionally found
positive interactions, with significantly higher detection frequen-
cies of RSV and other RNA viruses in AdV-positive samples.
Interpreting the mechanisms underlying these observations of
virus interference is complex. One unknown factor in this and
previous studies that may significantly contribute to the outcome
of a virus/virus interaction is the order of acquisition of infections.
For example, it has been hypothesised that the strong interferon
(IFN) response in the respiratory tract induced by HRV infection
may create an environment hostile to infection with other viruses,
such as RSV [36]. Even though RSV, through expression of NS-1,
can prevent IFN induction on infection of a cell [38], this
countermeasure may be largely ineffective in a respiratory tract
already induced into an antiviral state by prior infection with
HRV-C. If, however, RSV infected the respiratory tract first, then
this would have no effect on the subsequent susceptibility of the
individual to HRV. The rapid and highly cytopathic replication
cycle of rhinoviruses (and enteroviruses) that seems designed to
infect and escape from cells before IFN-mediated responses
become effective, may indeed have a more general interfering
effect on more sensitive RNA (and DNA viruses) that infect the
respiratory tract. Like RSV, successful colonisation of the
respiratory tract by coronaviruses, influenza and parainfluenza
viruses is dependent on a wide variety of evolved mechanisms to
evade intracellular defences [39,40] that are ineffective in pre-
sensitised cells induced by IFN into an antiviral state.
The effect of the order in which infections are acquired may
additionally influence the outcomes of co-infections with adeno-
viruses. AdVs express a plethora of evasion molecules that
substantially influences both the intracellular environment of the
cell it infects and also has a broader paracrine effect on cytokine
production in the respiratory tract and induction of local immunity
[41]. The frequent long term persistence of AdV infections
suggests that a more permissive environment for infection and
replication by other viruses may exist in the respiratory tract of
AdV-infected individual, and underlie the increased detection
frequencies of HRV-C, RSV and other respiratory viruses in co-
infected subjects (Fig. 5).
In summary, this study provides evidence for the substantial
clinical impact of HRV species C infections in young children,
their associations with respiratory disease and interfering effects on
susceptibility to other virus infections. Future studies should
illuminate the extent to which these observations are specific to
species C and which are shared with other rhinoviruses. The
recent surge of interest in rhinoviruses following the unexpected
discovery of species C will undoubtedly contribute to a major re-
appraisal of the roles of all three species in paediatric respiratory
disease.
Materials and Methods
Study Population and Samples
HRV-C was screened for in 2787 respiratory samples from
1540 patients (839 male, 675 female, 26 unknown) referred for
respiratory virus screening to the Specialist Virology Centre
(SVC), Royal Infirmary of Edinburgh between September 2006
and September 2007. The study incorporated previously collected
data from 456 samples collected in September, 2006 and
February, 2007 [18]. Samples comprised predominantly nasopha-
ryngeal or tracheal aspirates or swabs (n=1771), throat swabs
(n=619) and bronchoalveolar lavages (n=155), and were
routinely screened for the following respiratory viruses by PCR:
adenovirus (AdV), influenza A and B, parainfluenza virus types
1–3 (PIV1-3) and respiratory syncytial virus (RSV) using
previously described assays [42,43]. Samples were further tested
for human bocavirus (HBoV), human parechovirus (HPeV) [44],
human metapneumovirus (hMPV) [45] and coronaviruses HKU1,
OC43, 229E and NL63 (Gaunt et al., manuscript in preparation).
All but 94 (2.9%) of the tested samples were referred from hospital
inpatients or from Accident and Emergency Departments. Lower
respiratory tract infections (LRTIs) were identified in subjects
presenting with the following symptoms or diagnoses: bronchiol-
itis, chest infections, pneumonia, respiratory failure, shortness of
breath, apnoea and wheeze; upper respiratory tract infections
(URTIs) with coryza, sore throat, tonsillitis and tracheitis. Cough
was also classified as an URTI symptom, although we acknowl-
edge its additional potential association with lower respiratory
tract disease that leads to some potential misclassification of
disease categories in the absence of other respiratory symptoms.
Subjects with no relevant respiratory symptoms included the
referral categories of vomiting, diarrhoea, trauma and elective
cardiac surgery.
Ethical approval for anonymisation, archiving and screening of
diagnostic specimens was obtained from the Lothian Regional
Ethics Committee (08/S11/02/2). Information retained through
anonymisation included age band, partial postcode, any recorded
symptoms or clinical information, referral source, month of sample
collection, and results of other virological testing of each sample.
HRV-C Screening
RNA was extracted from clinical specimens as previously
described [18]. Reverse transcription of RNA extracted from
individual samples or pools of ten with random hexamers used the
RT system (Promega, United Kingdom) as described previously
[44]. Amplification of the HRV-C VP4/VP2-encoding region
used previously described primers and reaction conditions [18],
with a repositioned antisense inner primer (ATA GTR ATT TGY
TTD AGC CTA TCD GAV A; 59 base at position 888 numbered
here and elsewhere according to the HRV species B reference
sequence NC_001490) for selective amplification of HRV-C (see
Results). Underlined bases were designed to mismatch species A or
B (or both) sequences while being conserved within species C.
Positive samples were subsequently amplified with the four original
VP4/VP2 gene primers [18] and the amplicon directly sequenced.
Sequences generated from this study were edited and aligned with
published sequences using the Simmonics sequence editor v1.7
([46], http://www.virus-evolution.org). Published sequences in-
cluded the 9 complete genome sequences of HRV-C available on
GenBank and all species C VP4(/VP2) gene sequences available
on GenBank in August 2009. HRV-C types were putatively
assigned by phylogenetic analysis and uncorrected pairwise
distance measurements using the previously proposed 10%
divergence threshold [18]. Phylogenetic trees were constructed
by neighbour joining from 100 samplings of maximum-composite-
likelihood (MCL) distances using the MEGA 4.0 software package
[47] with pairwise deletion for missing data. VP4/VP2 sequences
generated in this study have been assigned GenBank accession
numbers GU294336-GU294480.
HRV-C positive samples identified on VP4/VP2 gene screening
were amplified in the 59UTR region for group assignment used a
HRV-C Diversity, Interactions
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WCC CCS G) used for both first and second round with the
antisense primers 573 (GAA ACA CGG ACA CCC AAA GTA
GT; outer) and 477 (TTA GCC RCA TTC AGG GGC CGG;
inner) using previously described reaction conditions [18]. For a
small number of samples that were unamplifiable by this method,
SuperScript III (Invitrogen) was used for reverse transcription and
first round PCR. HRV-C variants were assigned into species A
and C 59UTR groups by comparison with reference sequences of
known group between positions 280 and 370.
Statistical Analyses
Statistical tests were conducted using chi squared test with
Yates’ correction and 95% confidence intervals unless stated.
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